Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential 121.37% upside.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the ...

The market expects Stoke Therapeutics, Inc. (STOK) to deliver a year-over-year decline in earnings on higher revenues when it ...

Wrexham have taken a significant step toward boosting their stadium’s capacity, having officially submitted a planning application to Wrexham City Borough Council. The club aims to add an extra 2,250 ...

STOK Company Profile Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.

STOK has a tiny market cap of $629.50 million and a rather large “short interest” of more than 21%. Last quarter the company saw a nice beat on both earnings ($1.90) and revenues ($158 million ...

Here are some of the largest recent moves: FMR LLC added 2,376,741 shares (+1438.7%) to their portfolio in Q1 2025, for an estimated $15,805,327 MARSHALL WACE, LLP added 1,180,351 shares (+124.1% ...

The latest price target for Stoke Therapeutics (NASDAQ:STOK) was reported by Jefferies on July 18, 2025. The analyst firm set a price target for $30.00 expecting STOK to rise to within 12 months ...

Wrexham ’s Racecourse Ground will have a new name next season for the second time in its history following a lucrative sponsorship deal that is expected to earn the club a substantial seven ...

Treatment Arms: Patients in the active treatment arm will receive two 70mg loading doses (Day 1 and Week 8) followed by two 45mg maintenance doses (Week 24 and Week 40). All patients will continue to ...